CHARLES RIVER LABORATORIES INTERNATIONAL, INC（CRL）の決算・業績分析
CHARLES RIVER LABORATORIES INTERNATIONAL, INCの2025年有価証券報告書をAI分析。売上高$4.0B(-0.9%)。営業利益$25M。Industrials。
目次
CHARLES RIVER LABORATORIES INTERNATIONAL, INCの2025年度 業績サマリー
CHARLES RIVER LABORATORIES INTERNATIONAL, INC（証券コード: CRL）の2025年度決算・業績分析。売上高は$4.0B（前年比-0.9%）。営業利益は$25M（前年比-88.9%）。純利益は-$144M（前年比-750.1%）。有価証券報告書を基に、業績変化の要因・リスク・見通し・セグメント構成を AI が分析しました。
CHARLES RIVER LABORATORIES INTERNATIONAL, INCの2024年度 注目ポイント
※ 直近の2025年度XBRLデータは取込済みですが、AI分析は2024年度の10-Kを対象としています。
- Revenue grew 12.3% YoY to $4.0B (XBRL), driven by demand for non-clinical development services despite client restructuring (10-K).
- Net income surged 24.4% YoY to $486M (XBRL), with operating income rising 10.4% to $651M (XBRL).
- EBITDA margin held steady at 24.0% (XBRL), while net margin expanded to 12.2% (XBRL).
- Cash conversion cycle (CCC) remained at 91 days (XBRL), with receivables days at 72 and inventory days at 35 (XBRL).
- Debt-to-equity ratio of 1.26x (XBRL) indicates moderate leverage, with cash reserves at $277M (XBRL).
CHARLES RIVER LABORATORIES INTERNATIONAL, INCの売上高変化の要因
- •Total revenue reached $4.0B (XBRL), a 12.3% YoY increase. Growth was supported by demand for non-clinical development services despite client restructuring (10-K). Segment-specific revenue data is unavailable (N/A). The 5-year revenue CAGR of 12.8% (XBRL) reflects sustained expansion, though operating income growth (13.2% CAGR) outpaced revenue growth (10-K).
CHARLES RIVER LABORATORIES INTERNATIONAL, INCの営業利益変化の要因
- •Operating margin improved to 16.4% (XBRL), with net margin at 12.2% (XBRL). Operating income rose 10.4% YoY to $651M (XBRL), despite macroeconomic pressures and client cost-cutting (10-K). EBITDA of $955M (24.0% margin) (XBRL) highlights strong cash generation. Gross profit data is unavailable (N/A).
CHARLES RIVER LABORATORIES INTERNATIONAL, INCの事業リスクと対応
Financial risks from contract termination, underpricing, or delays (10-K).
Business disruptions from system upgrades or integration (10-K).
Cybersecurity risks from unauthorized access (10-K).
Failure to execute business strategy or achieve cost savings (10-K).
International operational risks from currency fluctuations or disasters (10-K).
Regulatory risks including non-compliance with data privacy and environmental laws (10-K).
Competitive risks from technology disruption and declining outsourcing trends (10-K).
CHARLES RIVER LABORATORIES INTERNATIONAL, INCの今後の見通し・業績予想
CHARLES RIVER LABORATORIES INTERNATIONAL, INCの事業内容
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) operates in the drug discovery and development sector, providing outsourced services such as non-human primate (NHP) supply and research models (10-K). Revenue is generated through contracts with biopharmaceutical clients, though segment-specific revenue breakdowns are not disclosed (N/A). Competitive risks include technology disruption and declining outsourcing trends (10-K). Key risks include contract termination, cybersecurity threats, and international operational challenges (10-K).
CHARLES RIVER LABORATORIES INTERNATIONAL, INCのAI業績分析レポート（2024年度）
Annual Report Analysis: CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) FY2024
Highlights
Business Overview
CRL provides drug discovery and development services, including NHP supply and research models (10-K). Revenue is driven by outsourcing contracts with biopharmaceutical clients. Competitive risks include technology disruption and declining outsourcing trends (10-K). Key risks include contract termination, cybersecurity threats, and international operational challenges (10-K).
Revenue Analysis
Total revenue reached $4.0B (XBRL), a 12.3% YoY increase. Growth was supported by demand for non-clinical development services despite client restructuring (10-K). Segment-specific revenue data is unavailable (N/A). The 5-year revenue CAGR of 12.8% (XBRL) reflects sustained expansion, though operating income growth (13.2% CAGR) outpaced revenue growth (10-K).
Profitability Analysis
Operating margin improved to 16.4% (XBRL), with net margin at 12.2% (XBRL). Operating income rose 10.4% YoY to $651M (XBRL), despite macroeconomic pressures and client cost-cutting (10-K). EBITDA of $955M (24.0% margin) (XBRL) highlights strong cash generation. Gross profit data is unavailable (N/A).
Balance Sheet Analysis
Total assets grew from $4.7B (FY2020) to $8.2B (FY2024) (XBRL), though declined to $7.5B (FY2025). Equity increased from $1.6B (FY2020) to $3.6B (FY2024) (XBRL), with a 43.9% equity ratio (XBRL). Current ratio of 1.52x (XBRL) indicates healthy liquidity. Total debt is not quantified (N/A), but debt-to-equity ratio is 1.26x (XBRL).
Cash Flow Analysis
Operating cash flow was $620M (XBRL), with free cash flow (FCF) at $12M (XBRL). Investing cash flow was -$608M (XBRL), reflecting capital expenditures or acquisitions (N/A). Financing cash flow was -$42M (XBRL), including $39M in share repurchases (XBRL). No dividends are mentioned (N/A).
Working Capital Analysis
Cash conversion cycle (CCC) was 91 days (XBRL), with receivables days at 72, inventory days at 35, and payables days at 16 (XBRL). Asset turnover of 0.49x (XBRL) suggests moderate efficiency.
Risks
Outlook
Management anticipates challenges from biopharmaceutical client restructuring, macroeconomic slowdown, patent expirations, and the Inflation Reduction Act's impact on drug pricing (10-K). No specific forward-looking guidance is provided (N/A).
Historical Time Series
| Metric | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | 2.3B | 2.6B | 2.9B | 3.5B | 4.0B | 4.1B |
| Operating Income | 331M | 351M | 433M | 590M | 651M | 617M |
| Net Income | 226M | 252M | 364M | 391M | 486M | 475M |
| Total Assets | 4.7B | 5.5B | 7.0B | 7.6B | 8.2B | 7.5B |
| Total Equity | 1.6B | 2.1B | 2.5B | 3.0B | 3.6B | 3.5B |
| Operating Cash Flow | 441M | 481M | 547M | 761M | 620M | 684M |
Industrialsの企業一覧
CHARLES RIVER LABORATORIES INTERNATIONAL, INCと同じ「Industrials」セクターの企業